Compare · INMB vs PALI
INMB vs PALI
Side-by-side comparison of INmune Bio Inc. (INMB) and Palisade Bio Inc. (PALI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMB and PALI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- PALI is the larger of the two at $342.0M, about 6.8x INMB ($50.5M).
- INMB has been more active in the news (10 items in the past 4 weeks vs 8 for PALI).
- INMB has more recent analyst coverage (10 ratings vs 7 for PALI).
- Company
- INmune Bio Inc.
- Palisade Bio Inc.
- Price
- -
- -
- Market cap
- $50.5M
- $342.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 10
- 8
- Recent ratings
- 10
- 7
INmune Bio Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.
Palisade Bio Inc.
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
Latest INMB
- INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
- INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
- Director Juda Scott exercised 14,801 shares at a strike of $1.40, increasing direct ownership by 21% to 86,404 units (SEC Form 4)
- Chief Scientific Officer Lowdell Mark William exercised 7,211 shares at a strike of $1.40, increasing direct ownership by 0.48% to 1,518,017 units (SEC Form 4)
- Chief Executive Officer Moss David J exercised 9,014 shares at a strike of $1.40, increasing direct ownership by 0.70% to 1,294,883 units (SEC Form 4)
- INmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
- INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
- INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
Latest PALI
- Director Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)
- Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
- Director Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)
- Chief Medical Officer Jones Mitchell Lawrence converted options into 131,167 shares and sold $106,536 worth of shares (51,880 units at $2.05), increasing direct ownership by 539% to 94,009 units (SEC Form 4) to satisfy tax liability
- CEO, CFO Finley John David exercised 335,300 shares at a strike of $0.00 and sold $303,343 worth of shares (146,798 units at $2.07), increasing direct ownership by 646% to 217,688 units (SEC Form 4) to cover withholding tax
- SEC Form 144 filed by Palisade Bio Inc.
- Director Baltera Robert Jr. bought $59,400 worth of shares (30,000 units at $1.98), increasing direct ownership by 9% to 366,904 units (SEC Form 4)
- Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
- Director Baltera Robert Jr. was granted 336,904 shares (SEC Form 4)
- SEC Form 3 filed by new insider Baltera Robert Jr.